RosenthalRLDreskinOHRosenthalLN. Plasma thromboplastin antecedent (PTA) deficiency: clinical, coagulation, therapeutic and hereditary aspects of a new hemophilia-like disease. Blood. 1955;10:120-131.
2.
Bolton-MaggsPH. Factor XI deficiency—resolving the enigma?Hematology Am Soc Hematol Educ Program. 2009:97-105.
3.
SantoroRPrejanòSIannaccaroP. Factor XI deficiency: a description of 34 cases and literature review. Blood Coagul Fibrinolysis. 2011;22:431-435.
4.
DugaSSalomonO. Congenital factor XI deficiency: an update. Semin Thromb Hemost. 2013;39:621-631.
5.
EmsleyJMcEwanPAGailaniD. Structure and function of factor XI. Blood. 2010;115:2569-2577.
6.
HeRChenDHeS. Factor XI: hemostasis, thrombosis, and antithrombosis. Thromb Res. 2012;129:541-550.
7.
SalomonOSteinbergDMSeligshonU. Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy. Haemophilia. 2006;12:490-493.
8.
FranchiniMManzatoFSalvagnoGMontagnanaMLippiG. The use of desmopressin in congenital factor XI deficiency. Ann Hematol. 2009;88:931-935.
9.
CastamanGRuggeriMRodeghieroF. Clinical usefulness of desmopressin for prevention of surgical bleeding in patients with symptomatic heterozygous factor XI deficiency. Br J Hematol. 1996;94:168-170.
10.
De AngelisVOraziBMSantarossaLMolaroG. Combined factor VIII and factor XI congenital deficiency: a case report. Haematologica. 1990;75:272-273.
11.
LivnatTTamarinIMorY. Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies. Thromb Haemost. 2009;102:487-492.
12.
LusherJMRobertsHRDavignonG. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia. 1998;4:790-798.
13.
ShapiroADGilchristGSHootsWKCooperHAGastineauDA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998;70:773-778.
14.
ShapiroAD. Recombinant factor VIIa in the treatment of bleeding in hemophilic children with inhibitors. Semin Thromb Hemost. 2000;26:413-419.
15.
NegrierCHayCR. The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa. Semin Thromb Hemost.2000;26:407-412.
16.
IngerslevJ. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost. 2000;26:425-432.
17.
BernMMSahudMZhukovOQuKMitchellWJr. Treatment of factor XI inhibitor using recombinant activated factor VIIa. Haemophilia. 2005;11:20-25.
18.
NielsenVG. Effects of aprotinin on plasma coagulation kinetics determined by thromboelastography: role of factor XI. Acta Anaesthesiol Scand. 2006;50:169-172.
19.
DirkmanDHankeAAGorlingerKPetersJ. Perioperative use of modified thrombelastography in factor XI deficiency: a helpful method to assess drug effects. Acta Anaesthesiol Scand. 2007;51:640-643.
20.
EscobarMARobertsHR. Less common congenital disorders of hemostasis. In: KitchensCSKesslerSMKonkleBA, eds. Consultative Hemostasis and Thrombosis. Philadelphia, PA: Elsevier Saunders; 2013:60-78.
